Effects of pioglitazone on arteriosclerotic-related factors and short term prognosis in patients with coronary disease and diabetes
MEI Bai-qiang
LIANG Qian
YANG Xi-li
OU Zhan-peng
WEN Yong-zhao
摘要：Background Thiazolidinediones (TZDs) not only improve insulin resistance,lowering blood sugar,also has anti-atherosclerotic effect. However, whether the protective effect on cardiovascular pioglitazone is still controversial.Methods Totally 98 patients with coronary disease and diabetes mellitus were randomly divided into pioglitazone group (n =48) receiving conventional therapy and pioglitazone (15 mg/day),and control group (n =50) merely receiving conventional therapy.The patients were followed up for 12 months.The plasma level of Plasminogen activator Inhibitor 1 (PAI-1) and P-selectin were detected at baseline and after treatment for 12 months by ELISA,and major adverse cardiac events (MACE) were studied.Results Pioglitazone therapy for 12 months was associated with a significant decrease of PAI-1 [(7.9 ± 1.4 vs 4.2 ± 0.5)ng/mL,P ＜0.05] and P-selectin [(16.6 ± 6.8 vs 12.4 ± 3.6)ng/mL,P ＜ 0.05],MACE was significantly lower in the pioglitazone group than in the control group [acute coronary syndrome (ACS):32.0％ vs 10.4％,P ＜ 0.05;target vessel revascularization:22.0％ vs 6.3％,P ＜ 0.05 ].Conclusions Pioglitazone can effectively reduce the plasma level of PAI-1, P-selectin and the occurrence of MACE in patients with coronary heart disease and diabetes mellitus.
机标关键词：
分类号：R541.4(心脏、血管（循环系）疾病)R587.2(内分泌腺疾病及代谢病)
论文发表日期：2011-10-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
英文信息